Compare Novavax Inc (NVAX) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs QUALCOMM, Inc. — how do they compare? Novavax Inc trades at $11 (market cap $1.85B), while QUALCOMM, Inc. trades at $178.58 (market cap $189.14B). The key difference: QUALCOMM, Inc. is far larger — about 102.2× Novavax Inc's market cap, and QUALCOMM, Inc. pays a 2.08% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and QUALCOMM, Inc. for 87 Days on average.
| NVAX | QCOM | |
|---|---|---|
Market Cap | $1.85B | $189.14B |
Volume | 8,362,562 | 7,874,672 |
Sector | Health | Technology |
52-Week High | $12.56 | $251.10 |
52-Week Low | $6.22 | $124.07 |
Typical Hold Time | 59 Days | 87 Days |
Enterprise Value | $1.43B | $196.10B |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 2.74% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported strong revenue of $1.12B in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Recent news highlights the company's pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in major markets.
Investment outlook remains speculative with analyst consensus heavily favoring Buy ratings (73.92%) but fundamental risks persist including negative cash flow trends and high debt levels. The stock offers potential upside from partnership expansions but faces significant execution and competitive risks in the biopharma sector.
Qualcomm (QCOM) trades at $176.01, down 2.79% on the day, with a bearish technical signal but strong fundamentals including 21.01% net income margin and 33.75% ROE. Recent earnings show mixed results with Q2 2026 missing expectations, while the company benefits from diversification into AI data centers and automotive sectors. Analyst consensus price target stands at $204.48, representing 16% upside potential from current levels.
The stock presents a compelling opportunity with reasonable valuation (P/E 20.24) and transformative AI partnerships, particularly the Amazon AWS deal offering up to $60 billion in potential revenue. Key risks include smartphone market dependence and competitive pressures in AI chips. Wall Street sentiment leans positive with 43% buy ratings despite recent technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
